Resolvin D1 (RvD1, 7S,8R,17S-trihydroxy-4Z,9E,11E,13Z,15E,19Z-docosahexaenoic acid) is a specialized pro-resolving mediator biosynthesized from DHA via sequential 15-LOX and 5-LOX enzymatic conversions. RvD1 actively orchestrates the resolution phase of inflammation by binding two G-protein coupled receptors (DRV1/GPR32 and ALX-FPR2) to halt neutrophil recruitment, enhance Efferocytosis, reprogram macrophages toward M2 phenotype, and promote tissue regeneration without immunosuppression. It represents a paradigm shift from anti-inflammatory suppression to pro-resolution activation.
Think of inflammation as a construction site after a disaster. The initial alarm brings emergency crews (neutrophils) who flood the area, break down damaged structures, and create controlled chaos to clear debris. Without a resolution signal, these crews keep arriving β sirens blaring, equipment piling up, traffic jammed β causing more damage than the original disaster.
RvD1 is the project manager who arrives precisely when demolition should stop and reconstruction should begin. She doesn't kick out the emergency crews (that would be immunosuppression). Instead, she: (1) posts a "SITE CLOSED" sign at the highway entrance, stopping new crews from arriving, (2) hands the existing crews a revised job description β "Your new role is cleanup and disposal, not demolition," transforming aggressive demolition teams into careful cleanup specialists who meticulously bag up debris (Efferocytosis), and (3) calls in the reconstruction teams (fibroblasts, endothelial cells) with architectural plans for tissue repair. She even briefs the cleanup crews to release "all-clear" signals (IL-10, TGF-beta) once they've finished, preventing future false alarms. The entire operation shifts from destruction to restoration, and the site returns to function faster with less collateral damage. Critically, she doesn't paralyze the workers β if a new disaster hits tomorrow, they can respond. She just ensures this specific job ends properly.
graph TD
A[DHA in cell membrane] -->|15-LOX| B[17S-H p DHA]
B -->|5-LOX| C[7S,8-epoxide intermediate]
C -->|Enzymatic hydrolysis| D["RvD1: 7S,8R,17S-trihydroxy-DHA"]
E[Aspirin-acetylated COX-2] -.->|Alternative route| B
D -->|Binds| F[DRV1/GPR32]
D -->|Binds| G[ALX/FPR2]
F --> H["GΞ±i activation"]
G --> I["GΞ±i/q activation"]
H --> J["β cAMP"]
H --> K[PI3K/Akt pathway]
I --> K
J --> L["β NF-ΞΊB nuclear translocation"]
K --> M["β SOCS3 expression"]
K --> N["β Rictor/mTORC2"]
L --> O["β TNF-Ξ±, IL-1Ξ², IL-6 production"]
M --> O
N --> P[Enhanced phagocytosis capacity]
K --> Q[Cytoskeletal reorganization for efferocytosis]
Step-by-Step Cascade:
-
Biosynthesis: DHA in phospholipid membranes β 15-LOX inserts oxygen at C17 position β 17S-hydroperoxy-DHA (17S-HpDHA) β 5-LOX creates 7S,8-epoxide intermediate β enzymatic hydrolysis yields RvD1 with critical stereochemistry (7S,8R,17S configuration)
-
Alternative aspirin-triggered pathway: Acetylated COX-2 (via Aspirin) produces 17R-HDHA β further conversion to AT-RvD1 (17R epimer)
-
Receptor activation:
- DRV1/GPR32 (primary): GΞ±i-coupled receptor β β cAMP β β PKA β prevents NF-ΞΊB nuclear translocation β β pro-inflammatory cytokine transcription
- ALX-FPR2: GΞ±i/GΞ±q-coupled β activates PI3K/Akt β β SOCS3 (suppressor of cytokine signaling) β JAK-STAT pathway inhibition β blocks TNF-Ξ±, IL-1Ξ², IL-6 signaling
-
Neutrophil arrest:
- RvD1 blocks CXCR3 and L-selectin expression on neutrophils β prevents transendothelial migration β existing neutrophils undergo apoptosis rather than necrosis
- β Leukotriene B4 (LTB4) production via 5-LOX inhibition β removes chemoattractant gradient
-
Macrophage Polarization:
- RvD1 β PI3K/Akt β Rictor/mTORC2 activation β metabolic shift toward oxidative phosphorylation (M2 phenotype)
- β Arginase expression β diverts arginine from iNOS (M1) to collagen synthesis pathway
- β CD206, CD163 mannose receptors β enhanced recognition of apoptotic cells
-
Enhanced Efferocytosis:
- RvD1 β Rac1 GTPase activation β actin cytoskeleton reorganization β membrane ruffling and pseudopod formation
- β MERTK, TIM-4 phosphatidylserine receptors β apoptotic cell binding capacity increased 3-5 fold
- Per macrophage ingestion capacity: 1-2 apoptotic neutrophils (baseline) β 5-7 apoptotic neutrophils (with RvD1 at 10 nM)
-
Anti-pain effects:
- Blocks TRPV1 and TRPA1 channels on nociceptors β β peripheral sensitization
- β spinal TNF-Ξ± and IL-1Ξ² β prevents central sensitization
- Direct action on dorsal root ganglia via GPR32 β β action potential frequency
-
Metabolic inactivation:
- Eicosanoid oxidoreductase converts bioactive RvD1 β 17-oxo-RvD1 (inactive) or 8-oxo-RvD1 (inactive)
- Dehydrogenation at positions 7, 8, or 17 β loss of biological activity
- Plasma half-life: ~2 minutes (requires continuous local biosynthesis for sustained effect)
Patient Populations:
RvD1 deficiency or impaired biosynthesis is clinically relevant in:
Metamodel Connections:
-
Metamodel 1 (Intermittent Living): RvD1 biosynthesis is enhanced during post-exercise recovery and refeeding after fasting β resolution programs activated during "rest" phases. Chronic stress (Cortisol excess) impairs 15-LOX activity β β RvD1 production.
-
Metamodel 3 (Selfish Brain): Brain produces RvD1 locally via microglia during neuroinflammation resolution. HIF-1 (brain hypoxia) β 15-LOX expression β compensatory β RvD1 in ischemic penumbra. This protects neurons but diverts DHA from systemic stores.
-
Metamodel 5 (Resolution of inflammation): RvD1 is the molecular embodiment of this metamodel. Resolution interval (R_i) is directly correlated with RvD1 levels. Lipid mediator class switching from pro-inflammatory PGE2/Leukotriene B4 to pro-resolving RvD1 determines whether inflammation resolves or becomes chronic.
Clinical Thresholds:
- Therapeutic range: 1-100 nM tissue concentration (10-100 ng/mL plasma equivalent)
- Minimal effective dose: 10 nM for macrophage reprogramming in vitro
- Pain relief threshold: 100 ng RvD1 intrathecally (animal models) reduces mechanical hyperalgesia 50% within 2 hours
- Biomarker monitoring: Plasma RvD1/Leukotriene B4 ratio: >0.5 indicates adequate resolution capacity; <0.2 predicts chronic inflammation
Intervention Implications:
-
DHA supplementation: 2-4 g/day EPA+DHA β substrate availability for RvD1 biosynthesis (but substrate alone insufficient if enzymes impaired)
-
Aspirin 81 mg/day: Triggers AT-RvD1 production via COX-2 acetylation β adjunct in cardiovascular protection beyond anti-platelet effects
-
Exercise timing: Moderate-intensity exercise (60-70% VOβmax) β transient β 15-LOX expression in leukocytes β optimal RvD1 window 2-6 hours post-exercise (resolution window)
-
Address enzyme inhibitors: Oxidative stress, hyperglycemia, trans-fats inhibit 15-LOX and 5-LOX β prioritize antioxidants (Vitamin E, Polyphenols), glycemic control, eliminate industrial seed oils
-
Future therapeutics: Synthetic RvD1 analogs (aspirin-triggered 17R-RvD1 more metabolically stable) under investigation for sepsis, ARDS, surgical recovery enhancement
-
Avoid NSAID interference: Non-aspirin NSAIDs block both COX-1 and COX-2 completely β prevent lipid mediator class switching β may prolong inflammation despite symptom relief
Evolutionary Context:
RvD1 biosynthetic capacity represents a conserved Resolution of inflammation program present in all vertebrates. Humans with CMAH gene loss and Uricase mutation have heightened baseline inflammation β may require higher RvD1 production capacity. Modern Omega-3 deficiency (omega-6:omega-3 ratio 20:1 vs. ancestral 1:1) creates evolutionary mismatch where substrate for RvD1 is chronically limited β chronic low-grade inflammation as default state.
- RvD1 structure: 7S,8R,17S-trihydroxy-4Z,9E,11E,13Z,15E,19Z-docosahexaenoic acid β stereochemistry is absolutely critical (epimers are inactive)
- Biosynthesized via sequential 15-LOX (C17 oxygenation) β 5-LOX (C7-C8 epoxide) β hydrolysis pathway
- Acts at nanomolar concentrations (10-100 nM = therapeutic range), making it 100-1000x more potent than DHA parent molecule
- Plasma half-life ~2 minutes due to rapid dehydrogenation by eicosanoid oxidoreductase β requires continuous local synthesis
- Binds two receptors: DRV1/GPR32 (primary, GΞ±i-coupled) and ALX-FPR2 (shared with Lipoxins, GΞ±i/GΞ±q-coupled)
- Increases macrophage phagocytosis capacity from 1-2 to 5-7 apoptotic neutrophils per macrophage
- Reduces TNF-Ξ±, IL-1Ξ², IL-6 production by 60-80% while increasing IL-10 by 200-300% (in vitro at 10 nM)
- Protective in animal models at doses: 100 ng intrathecal (pain), 1 ΞΌg/kg IV (sepsis), 300 ng intranasal (Alzheimer's)
- Aspirin-triggered variant (AT-RvD1, 17R epimer) is more metabolically stable with prolonged half-life
- RvD1 levels inversely correlate with disease severity in human studies: <0.5 pg/mL plasma in active IBD vs. 2-5 pg/mL in healthy controls
- Blocks TRPV1 and TRPA1 ion channels on nociceptors β direct analgesic effect independent of inflammation reduction
- Enhances bacterial clearance while resolving inflammation (unlike immunosuppressive drugs) β "resolution without immunosuppression"
- Production impaired by: chronic Cortisol elevation, Oxidative Stress, hyperglycemia, trans-fatty acids, omega-6 excess
- Omega-3 index (RBC EPA+DHA) >8% correlates with adequate RvD1 biosynthetic capacity
- First member of D-series resolvins identified (2002, Charles Serhan lab) β opened entire field of Specialized pro-resolving mediators (SPMs)
- DHA β RvD1 is biosynthesized from DHA via 15-LOX and 5-LOX; requires adequate DHA substrate availability for production
- 15-LOX β catalyzes first oxygenation step (C17) converting DHA to 17S-HpDHA precursor; enzyme activity rate-limiting in RvD1 synthesis
- 5-LOX β catalyzes second oxygenation (C7-C8 epoxide formation); same enzyme produces pro-inflammatory LTB4 from arachidonic acid (lipid mediator class switching)
- Specialized pro-resolving mediators (SPMs) β RvD1 is founding member of SPM family; shares resolution mechanisms with resolvins, protectins, maresins
- Efferocytosis β RvD1 enhances macrophage clearance of apoptotic neutrophils 3-5 fold via MERTK/TIM-4 receptor upregulation and cytoskeletal reorganization
- Macrophage Polarization β RvD1 drives M1βM2 transition via PI3K/Akt/mTORC2 pathway and metabolic shift to oxidative phosphorylation
- ALX-FPR2 β secondary RvD1 receptor (also binds lipoxin A4); mediates anti-neutrophil recruitment and enhanced phagocytosis effects
- Lipid mediator class switching β RvD1 production represents switch from pro-inflammatory PGE2/LTB4 biosynthesis to pro-resolution program
- Resolution of inflammation β RvD1 actively shortens resolution interval (Ri) by stopping neutrophil influx and accelerating debris clearance
- Omega-3 fatty acids β dietary EPA and DHA determine substrate pool for RvD1 biosynthesis; omega-6:omega-3 ratio affects resolution capacity
- Aspirin β acetylates COX-2 to produce 17R-HDHA β aspirin-triggered RvD1 (AT-RvD1) with enhanced metabolic stability
- NF-ΞΊB β RvD1 prevents NF-ΞΊB nuclear translocation via GΞ±i/cAMP/PKA pathway, blocking TNF-Ξ±, IL-1Ξ², IL-6 transcription
- TNF-Ξ± β RvD1 reduces TNF-Ξ± production by 60-80% and blocks TNF-Ξ± signaling via SOCS3 upregulation
- IL-1Ξ² β RvD1 inhibits NLRP3 inflammasome activation and IL-1Ξ² secretion; critical for terminating acute inflammation
- IL-10 β RvD1 increases IL-10 production 2-3 fold in M2 macrophages; creates anti-inflammatory feedback loop
- Neutrophil β RvD1 stops neutrophil tissue infiltration by blocking L-selectin and integrin expression; prevents excessive tissue damage
- COX-2 β aspirin-acetylated COX-2 produces RvD1 precursors; COX-2 thus has dual role (pro-inflammatory PGs early, pro-resolving SPMs late)
- Inflammatory pain β RvD1 blocks TRPV1/TRPA1 nociceptor channels and reduces spinal TNF-Ξ±/IL-1Ξ² to resolve inflammatory hyperalgesia
- Chronic inflammation β deficient RvD1 production or accelerated metabolism leads to failed resolution and chronic inflammatory states
- Type 2 Diabetes β adipose tissue macrophages in T2D show impaired RvD1 biosynthesis contributing to metabolic inflammation
- Obesity β visceral adipose tissue has low 15-LOX expression and high RvD1 degradation β failed resolution of metabolic inflammation
- Atherosclerosis β RvD1 promotes plaque resolution by enhancing macrophage efferocytosis of apoptotic foam cells and reducing necrotic core formation
- Sepsis β RvD1 improves survival in animal models by enhancing bacterial clearance while limiting excessive inflammation
- ARDS β RvD1 reduces pulmonary neutrophil infiltration and accelerates resolution of lung injury in preclinical models
- Inflammatory bowel disease β RvD1 levels inversely correlate with IBD disease activity; promotes intestinal barrier repair and mucosal healing